Vitamin B3 has a positive effect on damaged nerve cells in Parkinson's patients

June 6, 2018, Universitaet Tübingen
Nerve cells (purple) grown from stem cells derived from Parkinson’s patients. The nuclei are colored blue and the mitochondria green. Credit: Deleidi

Unsteady hands, stiff muscles and slow movements – all these are typical symptoms of Parkinson's disease. Some 220,000 people in Germany are affected by the disease, which becomes more likely to occur as people get older. It is caused by the loss of nerve cells in the brain and remains incurable. A team of researchers headed by Dr. Dr. Michela Deleidi at the Hertie Institute for Clinical Brain Research and the University of Tübingen is now reporting that nicotinamide riboside – a form of vitamin B3 – may offer a possible treatment. Initial results from the laboratory are promising: "This substance stimulates the faulty energy metabolism in the affected nerve cells and protects them from dying off," Deleidi explains. The researchers have published their study in the latest edition of the journal Cell Reports.

Damaged power plants lead to cell death

It is still not clear precisely what leads to the development of Parkinson's disease. Scientists do know that increasing levels of dopamine in in the substantia nigra region of the brain die off. Recently it has been recognized that the in these are damaged. Mitochondria are responsible for producing energy, making them the mini-power plants of the cell. When they go wrong, the cell may die. "In our study we aimed to investigate whether damaged mitochondria were merely a side effect or whether they cause Parkinson's disease," says Deleidi.

To find out, the researchers, working with international colleagues, took skin cell samples from patients with Parkinson's disease. They stimulated the cells to turn them into stem cells, which then developed into cells. The cells had a defect of what's known as the GBA gene – the most frequent risk gene for Parkinson's. Just like the 'real' nerve cells, their mitochondria – and consequently their energy production – were impaired.

Overhaul of cell power plants

The researchers then sought to stimulate the formation of new mitochondria. The coenzyme NAD plays an important role. The researchers 'fed' the cells with nicotinamide riboside, a form of vitamins B3 and a preliminary stage of the coenzyme. This led to a rise in the concentration of NAD in the cells. The result: "The nerve cells' energy budget improved considerably. New mitochondria formed and energy production rose."

In order to observe the effect of the vitamin in a living organism, the researchers took the further step of investigating flies with a GBA gene defect. As with Parkinson's patients, the flies' dopamine-rich nerve cells died off, and as they age, the flies have increasing difficulties in walking and climbing. Deleidi and her colleagues divided the flies into two groups. One group received feed enriched with the vitamin, the other did not. "The substance had a positive effect here as well. In the flies which were treated, far fewer nerve cells died off." Furthermore, they retained their mobility longer.

Possible treatment

"Our results suggest that the loss of mitochondria does indeed play a significant role in the genesis of Parkinson's ," Deleidi summarizes. "Administering nicotinamide riboside may be a new starting-point for treatment." Further studies are needed to determine whether the vitamin can be of real help with Parkinson's. The researchers are planning to test the effects of nicotinamide riboside on patients. Other studies have shown that it is well tolerated by healthy test subjects and boosts their energy metabolism as well," Deleidi says.

Explore further: Study uncovers cause of cell death in Parkinson's disease

More information: The NAD+ precursor, nicotinamide riboside, rescues mitochondrial defects and neuronal loss in iPSC and fly models of Parkinson's disease, Cell Reports, DOI: 10.1016/j.celrep.2018.05.009

Related Stories

Study uncovers cause of cell death in Parkinson's disease

February 26, 2018
A University of Guelph researcher has discovered one of the factors behind nerve cell death in Parkinson's disease, unlocking the potential for treatment to slow the progression of this fatal neurodegenerative disorder.

Gene could hold key to treating Parkinson's disease

October 19, 2015
Researchers at King's College London have identified a new gene linked to nerve function, which could provide a treatment target for 'switching off' the gene in people with neurodegenerative diseases such as Parkinson's disease.

New method maps the dopamine system in Parkinson's patients

February 14, 2018
With the aid of a PET camera, researchers from Karolinska Institutet in Sweden have developed a new method for investigating the dopamine system in the brains of patients suffering from Parkinson's disease. The method measures ...

Why a diabetes drug could help in Parkinson's disease

August 29, 2017
A diabetes drug might help in certain types of Parkinson's disease, reports a team of German brain researchers headed by Dr. Julia Fitzgerald at the Hertie Institute for Clinical Brain Research, the University of Tübingen ...

Vitamin K2: New hope for Parkinson's patients?

May 11, 2012
Neuroscientist Patrik Verstreken, associated with VIB and KU Leuven, succeeded in undoing the effect of one of the genetic defects that leads to Parkinson's using vitamin K2. His discovery gives hope to Parkinson's patients. ...

Getting closer to treatment for Parkinson's

January 23, 2017
More than 10 million people worldwide have Parkinson's disease. The cause of Parkinson's disease is unknown and thus no effective treatments exist. A study from the University of Bergen (UiB) suggests that the secret of the ...

Recommended for you

New transgenic model of Parkinson's illuminates disease biology

October 11, 2018
Parkinson's disease (PD) is a neurodegenerative disorder that presents clinically with abnormal movement and tremors at rest. In the brain, PD is marked by the accumulation of the protein, α-synuclein (αS), into clumps ...

Early Parkinson's patients waiting too long to seek medical evaluation

September 27, 2018
The time between diagnosis and the institution of symptomatic treatment is critical in the effort to find a cure for Parkinson's Disease (PD). A paper published in Nature Partner Journal: Parkinson's Disease notes too many ...

Molecule capable of halting and reverting neurodegeneration caused by Parkinson's disease identified

September 25, 2018
The small SynuClean-D molecule interrupts the formation of the alpha-synuclein amyloid fibres responsible for the onset of Parkinson's disease, and reverts the neurodegeneration caused by the disease. The study, headed by ...

Genomic dark matter activity connects Parkinson's and psychiatric diseases

September 20, 2018
Dopamine neurons are located in the midbrain, but their tendril-like axons can branch far into the higher cortical areas, influencing how we move and how we feel. New genetic evidence has revealed that these specialized cells ...

Gene therapy shown to remove core component of Parkinson's disease

September 14, 2018
An international team led by Rush researcher Jeffrey Kordower, Ph.D., has moved a step closer to developing a treatment to clear brain cells of a protein that is an integral cause of Parkinson's disease. The team published ...

ADHD may increase risk of Parkinson's disease and similar disorders

September 12, 2018
While about 11 percent of children (4-17 years old) nationwide have been diagnosed with attention-deficit hyperactivity disorder (ADHD), the long-term health effects of having ADHD and of common ADHD medications remains understudied. ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.